Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Actavis Group has announced that Robert Wessman has stepped down as the CEO of the company to focus on his investment company Salt Investments. However, Mr Wessman will continue to serve on the Actavis board of directors.
Subscribe to our email newsletter
The company has appointed Sigurdur Oli Olafsson, former deputy CEO of the company, as the new CEO. Mr Olafsson joined Actavis in 2003, after working for Pfizer UK from 1998 and moving to Pfizer US in 2001 to take a post in global research and development.
Mr Olafsson became the managing director of Actavis in the US in 2003. He has been deputy CEO since 2006. Olafsson holds a pharmacy degree from the University of Iceland.
Bjorgolfur Thor Bjorgolfsson, chairman of Actavis Group, said: “The board of directors of Actavis Group would like to thank Mr Wessman for his near ten year contribution to the group. Mr Wessman has played an important role in shaping and realizing Actavis’s vision and executing its successful strategy for growth.
“The board welcomes Sigurdur Oli Olafsson as the new CEO of the company. We know that under his leadership the company will continue to provide excellent service to its customers and maintain its role as one of the world’s leading companies in the development, manufacturing and sales of high quality generic drugs.”